Gosset Ownership
Private
Employees
~9
Therapeutic Areas
Stage
Other
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
TNA Therapeutics General Information
TNA Therapeutics is developing TNAT-101, an oral small molecule inhibitor of BCL3. The compound has shown preclinical efficacy in targeting cancer stem cells, reducing metastasis, and synergizing with immune checkpoint inhibitors. IND-enabling studies are ongoing to support the initiation of clinical trials in solid and hematological malignancies, including colorectal and metastatic breast cancers.
Contact Information
Primary Industry
Biotech
Corporate Office
New York, New York
United States
United States
Drug Pipeline
No pipeline data available
Key Partnerships
Innovate UK
TNA Therapeutics Funding
No funding data available
To view TNA Therapeutics's complete valuation and funding history, request access »